Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
0(0%)
Results Posted
15%(2 trials)

Phase Distribution

Ph phase_2
1
8%
Ph phase_4
8
62%
Ph phase_1
3
23%
Ph phase_3
1
8%

Phase Distribution

3

Early Stage

1

Mid Stage

9

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
8(61.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(13)

Detailed Status

Completed13

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (23.1%)
Phase 21 (7.7%)
Phase 31 (7.7%)
Phase 48 (61.5%)

Trials by Status

completed13100%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_3

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

NCT01316107
completedphase_4

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

NCT00259168
completedphase_4

Study of the Durability of Glycemic Control With Nateglinide

NCT00858013
completedphase_4

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

NCT00402909
completedphase_1

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

NCT02088918
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01316107Phase 3

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Completed
NCT00259168Phase 4

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

Completed
NCT00858013Phase 4

Study of the Durability of Glycemic Control With Nateglinide

Completed
NCT00402909Phase 4

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Completed
NCT02088918Phase 1

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Completed
NCT01030952Phase 4

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Completed
NCT00238472Phase 4

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Completed
NCT01159158Phase 1

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

Completed
NCT01160029Phase 1

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition

Completed
NCT00212290Phase 4

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Completed
NCT00437918Phase 4

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Completed
NCT00189774Phase 2

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Completed
NCT00319189Phase 4

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13